Creative Planning
RVNC

Creative Planning’s Revance Therapeutics, Inc. RVNC Stock Holding History

Creative Planning’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,136
Closed -$52.1K – 3786
2024
Q4 		$52.1K Buy
17,136
+6,278
+58% +$27.3K ﹤0.01% 3245
2024
Q3 		$56.4K Buy
+10,858
New +$54K ﹤0.01% 3083
2024
Q2 		– Sell
-11,551
Closed -$56.8K – 3194
2024
Q1 		$56.8K Buy
+11,551
New +$68.4K ﹤0.01% 2774
2023
Q2 		– Sell
-53
Closed -$1.71K – 2872
2023
Q1 		$1.71K Buy
+53
New +$1.65K ﹤0.01% 2524
2021
Q4 		– Sell
-9,113
Closed -$254K – 2235
2021
Q3 		$254K Hold
9,113
– – ﹤0.01% 1698
2021
Q2 		$270K Sell
9,113
-23
-0.3% -$663 ﹤0.01% 1620
2021
Q1 		$255K Buy
+9,136
New +$253K ﹤0.01% 1901
2017
Q3 		– Sell
-1,000
Closed -$26K – 3820
2017
Q2 		$26K Buy
1,000
+900
+900% +$20.1K ﹤0.01% 3006
2017
Q1 		$2K Hold
100
– – ﹤0.01% 4334
2016
Q4 		$2K Buy
+100
New +$1.68K ﹤0.01% 4323

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Creative Planning's RVNC Position: Q1 2025 in Review

Creative Planning sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 17,136 shares — an estimated $52.1K sold.

Creative Planning first reported a position in RVNC in Q4 2016 and held it in 10 quarters. The position peaked at $270K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Creative Planning reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Creative Planning sold 17,136 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $52.1K.
  • Creative Planning first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 10 quarters.
  • Creative Planning's Revance Therapeutics, Inc. position peaked at $270K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Creative Planning's 13F filing for Q1 2025, filed 15 May 2025.